Keynote-C93/GOG-3064/ENGOT-EN15: Phase 3, randomized, open-label study of first-line pembrolizumab versus platinum-doublet chemotherapy in mismatch repair deficient advanced or recurrent endometrial carcinoma Meeting Abstract
| Authors: | Slomovitz, B.; Cibula, D.; Gultekin, M.; Mirza, M.; Maćkowiak-Matejczyk, B.; Taylor, A.; Romero, I.; Colombo, N.; Korach, J.; Zhu, J.; Gilbert, L.; Hasegawa, K.; Kim, J. W.; Baron-Hay, S.; Makker, V.; Coleman, R. L.; Orlowski, R. J.; Zhou, X.; Khemka, V.; Pignata, S. |
| Abstract Title: | Keynote-C93/GOG-3064/ENGOT-EN15: Phase 3, randomized, open-label study of first-line pembrolizumab versus platinum-doublet chemotherapy in mismatch repair deficient advanced or recurrent endometrial carcinoma |
| Meeting Title: | IGCS 2022 Annual Meeting |
| Journal Title: | International Journal of Gynecological Cancer |
| Volume: | 32 |
| Issue: | Suppl. 3 |
| Meeting Dates: | 2022 Sep 29-Oct 1 |
| Meeting Location: | New York, NY |
| ISSN: | 1048-891X |
| Publisher: | Lippincott Williams & Wilkins |
| Date Published: | 2022-12-01 |
| Start Page: | A230 |
| Language: | English |
| ACCESSION: | WOS:000899252300481 |
| DOI: | 10.1136/ijgc-2022-igcs.525 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: TP016/#1442 -- Source: Wos |
